Skip to main content

albuterol sulfate; budesonide

Generic: ALBUTEROL SULFATE; BUDESONIDE·Brand: AIRSUPRA

albuterol sulfate; budesonide: sourced relationships with 1 company · 1 FDA decision.

albuterol sulfate; budesonide evidence translation

What we can confirm

What it means

Source-backed records connect albuterol sulfate; budesonide to AZN; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could albuterol sulfate; budesonide → AZN affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

Dated Pipeline Records (2)
CompanyDated record stage
ASTRAZENECA PLC (AZN)
Reported 2023-01-10 · Current development: unknownSource
Approved
ASTRAZENECA PLC (AZN)
Reported 2023-01-10 · Current development: unknownSource
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE AIRSUPRA is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. AIRSUPRA is a combination of albuterol, a beta 2 -adrenergic agonist and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. ( 1 )(AZN)FDA ↗
NDA214070Type 4 - New CombinationStandardInhalationAerosol, Metered

Frequently asked questions

Which companies have sourced relationships with albuterol sulfate; budesonide?

albuterol sulfate; budesonide has dated SEC/FDA relationship records for ASTRAZENECA PLC.

What is albuterol sulfate; budesonide's latest FDA decision?

The most recent tracked FDA decision for albuterol sulfate; budesonide is Approval for 1 INDICATIONS AND USAGE AIRSUPRA is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. AIRSUPRA is a combination of albuterol, a beta 2 -adrenergic agonist and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. ( 1 ), dated January 10, 2023.